Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world prophylaxis of chemoradiotherapy-induced nausea and vomiting with dolasetron mesylate
ChiCTR2500101688Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dolasetron in Non-hematologic malignancy, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Proportion of subjects without vomiting in the first cycle. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
dolasetron
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on ChiCTR2500101688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101688.